Across TCGA pan-cancer cohorts, MT-ATP6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MT-ATP6 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MT-ATP6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MT-ATP6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where MT-ATP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.809	0.488	.001	27	view →
LUAD	DFS	Median	II,III,IV	0.309	0.660	.007	18	view →
CCRCC	DFS	Median	II,III,IV	0.399	0.943	.021	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MT-ATP6 tumor-vs-normal RNA expression · all MT-ATP6 data types